CF Technology Transfer Unit (SPARK@FLI)
Translating discoveries from bench to bedside is a challenging process and allows us do advance scientific discoveries and ensures that government-funded research translates into improved health for our society. The SPARK training program helps to understand clinical needs, develops a target product profile and strengthens project management abilities. These essential tools not only increase the likelihood of success, but also help decrease both the cost and time required to accomplish this goal (“de-risking”).
The Transfer Unit supports research labs to develop small molecules or biologicals or treatments of unmet clinical needs, respectively, with the aim to advance projects for any indication with high potential impact. To achieve this goal we utilize a variety of molecular and cell based techniques as well as different animal models.
The facility offers advisory, financial and personnel support, including:
- Funds to asses and to de-risk your project
- Funds to actually run a project
- Implementation and execution of assays, e.g. toxicity assay, dose-response assay
- Advice from SPARK advisory board, consisting of experts with translational experience
- Mentored project management support
- Help to establish defensible Intellectual Property
- Training on what translation is all about
- Education on drug and diagnostic development
- Introduction to of the SPARK international network
We are currently using and offering support for the following assays and techniques:
- Cell culture (primary and tumor cell lines, mouse and human)
- Toxicity tests
- Viability tests
- Protein purification - see also Core Service Protein Production
- Western Blot analysis, RNA purification
- qPCR analysis
- siRNA & shRNA - see also Core Facility Functional Genomics
- Virus production
- Transfection
- Transduction
New SPARK FLI Teams 2024 - German
New SPARK FLI Teams 2024 - English
For further questions, please contact the CF manager Sonja Schätzlein.
Call open! Böhringer Ingelheim openME | Deadline June 5th 2024
How would you propose to demonstrate the utility of TRPA1 antagonist BI-0111 in novel human disease indications? Have a chance to access our potent and selective TRPA1 antagonist BI-0111 via opnMe. With a novel research hypothesis in the context of human diseases, you would benefit from interacting with Boehringer Ingelheim scientists as well as get collaborative funding up to 250,000 euros if your proposal was selected. Learn more...
Call open! GO-Bio next: Den Sprung vom Labor in die Wirtschaft schaffen | Deadline 15. September 2024
Das Bundesministerium für Bildung und Forschung (BMBF) hat mit „GO-Bio next“ die erfolgreiche Förderrichtlinie zur Unterstützung von gründungsorientierten Forschungsprojekten in den Lebenswissenschaften neu aufgelegt hat. Nähere Informationen finden Sie hier:
Am 18. Juni 2024, 9:00 -11:00 Uhr, laden wir Sie zu einer virtuellen Informationsveranstaltung ein, zu der Sie sich hier anmelden können.
SPARK Europe Webinar Series - Programm 2024
- Wednesday, June 5, 2024 / SPARK FLI / Drug Development in Industry: Integration Pharmacokinetics and Pharmacodynamics / Dr. Peter Florian
- Wednesday, July 3, 2024 / SPARK Masaryk University / Personalised Immunotherapy for Treatment of Rare Diseases / Speakers from Central European Advanced Therapy and Immunotherapy Centre (CREATIC)
Internal users:
A free sample of the published book, “SPARK: A Practical Guide to Drug Development in Academia”, by Daria Mochly-Rosen and Kevin Grimes will be given to our SPARKees.
External users:
External guests are welcome to join our educational forum series (Wednesday 5-7PM in Golgi). Project presentations are only accessible with signed CDA.
Additional Links:
Team (incomplete due to Data protection)
For publications of individual CF members: publications search
Contact
Sonja Schätzlein
CF Manager
+49 3641 65-6836
sonja.schaetzlein@~@leibniz-fli.de
Christoph Kaether
Scientific Supervisor
christoph.kaether@~@leibniz-fli.de
Overview CF Technology Transfer (SPARK)
